The trial involving 348 samples (200 women with
ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity
(90%), with a high overall Receiver Operating Characteristic (ROC)-Area Under the Curve (AUC) score
for accuracy of 0.92. In addition, the test detected all subtypes and stages of ovarian cancer in the samples
with the performance of the test between early-stage and late stage ovarian cancer not statistically different
(p>0.5).
The BARD1 Ova
This will put them on the map for sure!
Ann: OVARIAN CANCER CLINICAL STUDY RESULTS, page-3
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
0.010(2.04%) |
Mkt cap ! $46.00M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 50.0¢ | 47.5¢ | $35.73K | 73.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 13954 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 6167 | 5 |
View Market Depth
| Last trade - 15.55pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
50.0¢ |
Change
0.010 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 48.5¢ | 50.0¢ | 47.5¢ | 18914 | ||
| Last updated 15.55pm 21/05/2024 ? | |||||
| IIQ (ASX) Chart |